Oral Mucositis

TGF-Beta 3 Phase II Trials Initiated

Published in Cancer Weekly, March 17th, 1997

Oncogene Science, Inc., Uniondale, New York, announced that Novartis Pharma AG, Basel, Switzerland, a collaborative partner for the development of TGF-Beta 3, has initiated multi-center Phase II clinical studies in Europe, South America, and the United States for the prevention of oral mucositis in cancer patients undergoing chemotherapy.

Approximately 300 breast cancer and lymphoma patients undergoing high-dose chemotherapy are expected to participate in the Phase II trials.

Oral mucositis is a painful, often debilitating condition characterized by mouth and throat lesions that frequently occur when chemotherapeutic agents, which act against...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-03-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry